Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Research analysts at Maxim Group issued their Q3 2026 earnings per share estimates for Bradmer Pharmaceuticals in a research note issued on Friday, August 7th. Maxim Group analyst M. Galinko anticipates that the company will post earnings per share of ($0.61) for the quarter. Maxim Group also issued estimates for Bradmer Pharmaceuticals’ Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.64) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($1.69) EPS, Q3 2027 earnings at ($1.09) EPS, Q4 2027 earnings at ($0.60) EPS, FY2027 earnings at ($4.04) EPS and FY2028 earnings at $0.00 EPS.
Separately, Chardan Capital raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Bradmer Pharmaceuticals currently has a consensus rating of “Buy”.
Bradmer Pharmaceuticals Stock Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- China’s Athleisure Boom Is Not Lifting Every Brand Equally
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
